Cited by 124Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerBioactive Compounds and Antitumor Agents

The DOI matches its Crossref record; 113 of the 119 references it cites were found in a registry or an index.

The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment

Open access

Huang, Yaxin, Sun, Guohui, Sun, Xiaodong, Li, Feifan, Zhao, Lijiao, Zhong, Rugang, Peng, Yongzhen·2020·Cancers

DOI 10.3390/cancers12113332PMC PMC7696079

Open this paper in CoChat — free account Open PDF

Abstract

Lonidamine (LND) has the ability to resist spermatogenesis and was first used as an anti-spermatogenic agent. Later, it was found that LND has a degree of anticancer activity. Currently, LND is known to target energy metabolism, mainly involving the inhibition of monocarboxylate transporter (MCT), mitochondrial pyruvate carrier (MPC), respiratory chain complex I/II, mitochondrial permeability transition (PT) pore, and hexokinase II (HK-II). However, phase II clinical studies showed that LND alone had a weak therapeutic effect, and the effect was short and reversible. Interestingly, LND does not have the common side effects of traditional chemotherapeutic drugs, such as alopecia and myelosuppression. In addition, LND has selective activity toward various tumors, and its toxic and side effects do not overlap when combined with other chemotherapeutic drugs. Therefore, LND is commonly used as a chemosensitizer to enhance the antitumor effects of chemotherapeutic drugs based on its disruption of energy metabolism relating to chemo- or radioresistance. In this review, we summarized the combination treatments of LND with several typical chemotherapeutic drugs and several common physical therapies, such as radiotherapy (RT), hyperthermia (HT), and photodynamic therapy (PDT), and discussed the underlying mechanisms of action. Meanwhile, the development of novel formulations of LND in recent years and the research progress of LND derivative adjudin (ADD) as an anticancer drug were also discussed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/cancers12113332

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Molecular structures of (A) LND and (B) ADD. LND and ADD are indazole derivatives. Their chemical names are 1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid and 1-(2,4-dichlorobenzyl)-1H-indazole-3-carbohydrazide, respectively.CC BY · PubMed Central

Figure 2 Underlying mechanisms of LND-mediated antitumor activity. (1) LND inhibits the lactate export and the uptake of pyruvate into mitochondria by the inhibition of proton-linked monocarboxylate transporter (MCT) and mitochondrial pyruvate carrier (MPC), respectively. (2) LND inhibits complexes I and II by interfering with ubiquinone reduction, leading to ATP depletion and ROS production. (3) LND affects the mitochondrial permeability transition (PT) pore which is under the control of the members of the Bcl-2 family. (4) LND inhibits glycolysis through the inhibition of hexokinase II (HK-II), thereby reducing the levels of NADPH and glutathione (GSH) in part by the inhibition of the pentose phosphate pathway (PPP) flux.CC BY · PubMed Central

Figure 3 Targeting three key ways to cut off the tumor’s energy and matter supply. Cancer cells obtain energy and matter mainly through glycolysis, glutaminolysis, and fatty acid synthesis. Cutting off these three pathways can inhibit tumor growth.CC BY · PubMed Central

Figure 4 Synergistic model of DON in combination with LND and orlistat. LND inhibits glycolysis by inhibiting hexokinase II (HK-II), DON inhibits glutaminolysis by inhibiting kidney-type glutaminase (GLS1), and Orilistat inhibits fatty acid synthesis by inhibiting the FA synthase.CC BY · PubMed Central

Figure 5 Synergistic model of the combination of ATO and LND. The combination of ATO and LND could inhibit the phosphorylation of AKT, mTOR, and ERK in the MEK/ERK and AKT/mTOR signaling pathways, respectively, and reduce cell proliferation.CC BY · PubMed Central

Figure 6 Synergistic model of the combination of MAT and LND for the treatment of human myeloid leukemia cells. MAT can inhibit the binding of c-Myc to HK-II gene intron. When in combination with LND, it can reduce the expression of HK-II and inhibit the glycolysis.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,508
Photodynamic therapy – mechanisms, photosensitizers and combinations
Kwiatkowski, S., Knap, B., Przystupski, D., Saczko, J., Kędzierska, E., Knap-Czop, K., Kotlińska, J., Michel, O., Kotowski, K., & Kulbacka, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.049 · Cited by 2,173
Targeting cancer metabolism: a therapeutic window opens
Heiden, M. G. V. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,443
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S. P., Crijns, H. J. G. M., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,425
Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer
DeBerardinis, R. J., & Cheng, T. (2010) · Oncogene · doi:10.1038/onc.2009.358 · Cited by 1,365
Mechanisms of action of arsenic trioxide.
Miller, W. H., Schipper, H. M., Lee, J. S., Singer, J. W., & Waxman, S. (2002) · PubMed · Cited by 941
Heat Shock Proteins: Endogenous Modulators of Apoptotic Cell Death
Garrido, C., Gurbuxani, S. K., Ravagnan, L., & Kroemer, G. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5427 · Cited by 790
A microenvironmental model of carcinogenesis
Gatenby, R. A., & Gillies, R. J. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2255 · Cited by 741
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 731
Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity
Kridel, S. J., Axelrod, F. T., Rozenkrantz, N., & Smith, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3645 · Cited by 610
DNA Cross-Linking Agents as Antitumor Drugs
Rajski, S. R., & Williams, R. M. (1998) · Chemical Reviews · doi:10.1021/cr9800199 · Cited by 596
Hyperthermia adds to chemotherapy
Issels, R. D. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.038 · Cited by 545
Oncogenic K‐Ras decouples glucose and glutamine metabolism to support cancer cell growth
Gaglio, D., Metallo, C. M., Gameiro, P. A., Hiller, K., Danna, L. S., Balestrieri, C., Alberghina, L., Stephanopoulos, G., & Chiaradonna, F. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.56 · Cited by 492
NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNA
Denny, B. J., Wheelhouse, R. T., Stevens, M. F. G., Tsang, L. L. H., & Slack, J. A. (1994) · Biochemistry · doi:10.1021/bi00197a003 · Cited by 442
Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics
Gerweck, L. E., Vijayappa, S., & Kozin, S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0024 · Cited by 362
Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells
Reuter, S., Eifes, S., Dicato, M. A., Aggarwal, B. B., & Diederich, M. F. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.07.031 · Cited by 340
Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis
Cheng, G., Zhang, Q., Pan, J., Lee, Y., Ouari, O., Hardy, M., Zielonka, M., Myers, C. R., Zielonka, J., Weh, K. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10042-1 · Cited by 255
Molecular targets of curcumin.
Lin, J.-K. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-46401-5_10 · Cited by 230
Mechanism of antineoplastic activity of lonidamine
Nath, K., Guo, L., Nancolas, B., NELSON, D. S., Shestov, A. A., Lee, S., Roman, J., Zhou, R., Leeper, D. B., Halestrap, A. P., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.08.001 · Cited by 219
The Potential Role of Systemic Buffers in Reducing Intratumoral Extracellular pH and Acid-Mediated Invasion
Silva, A. S., Yunes, J. A., Gillies, R. J., & Gatenby, R. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2394 · Cited by 213
Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore
Ravagnan, L., Marzo, I., Costantini, P., Susín, S. A., Zamzami, N., Petit, P. X., Hirsch, F., Goulbern, M., Poupon, M., Miccoli, L., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202625 · Cited by 207
The roles of glucose metabolic reprogramming in chemo- and radio-resistance
Lin, J., Xia, L., Liang, J., Han, Y., Wang, H., Oyang, L., Tan, S., Tian, Y., Rao, S., Chen, X., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1214-z · Cited by 193
Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine
Guo, L., Shestov, A. A., Worth, A. J., Nath, K., NELSON, D. S., Leeper, D. B., Glickson, J. D., & Blair, I. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.697516 · Cited by 187
Development of EGFR-Targeted Polymer Blend Nanocarriers for Combination Paclitaxel/Lonidamine Delivery To Treat Multi-Drug Resistance in Human Breast and Ovarian Tumor Cells
Milane, L. S., Duan, Z., & Amiji, M. M. (2010) · Molecular Pharmaceutics · doi:10.1021/mp1002653 · Cited by 165
Two New Male Contraceptives Exert Their Effects by Depleting Germ Cells Prematurely from the Testis1
Cheng, C. Y., Silvestrini, B., Grima, J., Mo, M., Zhu, L.-J., Johansson, E., Saso, L., Leone, M.-G., Palmery, M., & Mruk, D. D. (2001) · Biology of Reproduction · doi:10.1095/biolreprod65.2.449 · Cited by 154
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas
Kaina, B., & Christmann, M. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.04.007 · Cited by 147
Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro
Khdair, A. A., Handa, H., Mao, G., & Panyam, J. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.017 · Cited by 129
Heat shock proteins and the heat shock response during hyperthermia and its modulation by altered physiological conditions
Horowitz, M., & Robinson, S. D. M. (2007) · Progress in brain research · doi:10.1016/s0079-6123(06)62021-9 · Cited by 128
Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy
Cervantes-Madrid, D., Romero, Y., & Dueñas‐González, A. (2015) · BioMed Research International · doi:10.1155/2015/690492 · Cited by 125
Direct and indirect photodynamic therapy effects on the cellular and molecular components of the tumor microenvironment
Sanabria, L. M., Rodríguez, M. E., Cogno, I. S., Vittar, N. B. R., Pansa, M. F., Lamberti, M. J., & Rivarola, V. A. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.10.001 · Cited by 120
Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia
Zhou, J., Zhang, Y., Li, J., Li, X., Hou, J., Zhao, Y., Liu, X., Han, X., Hu, L., Wang, S., et al. (2009) · Blood · doi:10.1182/blood-2009-07-230805 · Cited by 116
Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer
Li, Q., Zhang, D., Chen, X., He, L., Li, T., Xu, X., & Li, M. (2015) · Scientific Reports · doi:10.1038/srep16082 · Cited by 114
Prolonged Biologically Active Colonic Tissue Levels of Curcumin Achieved After Oral Administration—A Clinical Pilot Study Including Assessment of Patient Acceptability
Irving, G. R. B., Howells, L. M., Sale, S., Kralj‐Hans, I., Atkin, W. S., Clark, S. K., Britton, R. G., Jones, D. J. L., Scott, E. N., Berry, D. P., et al. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0281 · Cited by 111
Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration
Zhang, Y., Zhang, H., Yu, P., Liu, Q., Liu, K., Duan, H., Luan, G., Yagasaki, K., & Zhang, G. (2009) · Cytotechnology · doi:10.1007/s10616-009-9211-2 · Cited by 108
Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways
Li, N., Zhang, C.-X., Wang, X., Zhang, L., Ma, X., Zhou, J., Ju, R.-J., Li, X., Zhao, W., & Lü, W.-L. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.055 · Cited by 99
Problems of glioblastoma multiforme drug resistance
Stavrovskaya, A. A., Сакенович, Ш. С., & Rybalkina, E. Y. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916020036 · Cited by 95
Molecular Targets of Arsenic Trioxide in Malignant Cells
Miller, W. H. (2002) · The Oncologist · doi:10.1634/theoncologist.7-suppl_1-14 · Cited by 94
Curcumin Stimulates Reactive Oxygen Species Production and Potentiates Apoptosis Induction by the Antitumor Drugs Arsenic Trioxide and Lonidamine in Human Myeloid Leukemia Cell Lines
Sánchez, Y., Simón, G. P., Calviño, E., de Blas, E., & Aller, P. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.168344 · Cited by 88
Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis
Sordet, O., Rébé, C., Leroy, I., Bruey, J., Garrido, C., Miguet‐Alfonsi, C., Lizard, G., Plenchette, S., Corcos, L., & Solary, É. (2001) · Blood · doi:10.1182/blood.v97.12.3931 · Cited by 87
Potentiation of radiation effects on two murine tumors by lonidamine.
Kim, J. H., Alfieri, A. A., Kim, S. H., & Young, C. W. (1986) · PubMed · Cited by 85
Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin
Nath, K., NELSON, D. S., Heitjan, D. F., Leeper, D. B., Zhou, R., & Glickson, J. D. (2014) · NMR in Biomedicine · doi:10.1002/nbm.3240 · Cited by 85
Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma
Gourdier, I., Rio, M. D., Crabbé, L., Candeil, L., Copois, V., Ychou, M., Auffray, C., Martineau, P., Mechti, N., Pommier, Y. G., et al. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03347-1 · Cited by 83
5-ALA mediated photodynamic therapy induces autophagic cell death via AMP-activated protein kinase
Ji, H.-T., Chien, L., Lin, Y.-H., Chien, H., & Chen, C. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-91 · Cited by 79
Multi-responsive albumin-lonidamine conjugated hybridized gold nanoparticle as a combined photothermal-chemotherapy for synergistic tumor ablation
Ruttala, H. B., Ramasamy, T., Poudel, B. K., Ruttala, R. R. T., Jin, S. G., Choi, H., Ku, S., Yong, C. S., & Kim, J. O. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.11.003 · Cited by 78
Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator
Thiabaud, G., McCall, R., He, G., Arambula, J. F., Siddik, Z. H., & Sessler, J. L. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201604236 · Cited by 71
Preferential effects of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on pulmonary glutathione reductase and glutathione/glutathione disulfide ratios: possible implications for lung toxicity.
Smith, A. C., & Boyd, M. R. (1984) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21862-6 · Cited by 70
Inhibition of the recovery from potentially lethal damage by lonidamine
Hahn, G. M., Kersen, I. V., & Silvestrini, B. (1984) · British Journal of Cancer · doi:10.1038/bjc.1984.232 · Cited by 65
Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs
Price, G. S., Page, R. L., Riviere, J. E., Cline, J. M., & Thrall, D. Ε. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050460 · Cited by 62
Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells
Xu, L., Gao, C., Wu, Y., Cheng, C. Y., Xia, W., & Zhang, Z. (2015) · Journal of Materials Chemistry B · doi:10.1039/c4tb01764a · Cited by 61
Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy
Golding, J. P., Wardhaugh, T., Patrick, L., Turner, M., Phillips, J. B., Bruce, J. I., & Kimani, S. G. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.391 · Cited by 60
Doxorubicin and adjudin co-loaded pH-sensitive nanoparticles for the treatment of drug-resistant cancer
Wang, Q., Zou, C., Wang, L., Gao, X., Wu, J., Tan, S., & Wu, G. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.061 · Cited by 55
Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation
Calviño, E., Estañ, M. C., Simón, G. P., Sancho, P., Boyano-Adánez, M. D. C., de Blas, E., Bréard, J., & Aller, P. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.08.017 · Cited by 53
Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems
Silvestrini, B., Hahn, G. M., Cioli, V., & Martino, C. D. (1983) · British Journal of Cancer · doi:10.1038/bjc.1983.30 · Cited by 52
Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant ehrlich ascites tumor cells through modulation of energy metabolism
Floridi, A., Bruno, T., Miccadei, S., Fanciulli, M., Federico, A., & Paggi, M. G. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00054-9 · Cited by 51
Effects of combinations of azaserine and of 6-diazo-5-oxo-L-norleucine with purine analogs and other antimetabolites on the growth of two mouse mammary carcinomas.
Tarnowski, G. S., & Stock, C. (1957) · PubMed · Cited by 50
Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification
Ben‐Yoseph, O., Lyons, J. C., Song, C. W., & Ross, B. D. (1998) · Journal of Neuro-Oncology · doi:10.1023/a:1005819604858 · Cited by 50
3-Bromopyruvate regulates the status of glycolysis and BCNU sensitivity in human hepatocellular carcinoma cells
Sun, X., Sun, G., Huang, Y., Hao, Y., Tang, X., Zhang, N., Zhao, L., Zhong, R., & Peng, Y. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113988 · Cited by 49
Self-citation
31P and 1H MRS of DB‐1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan
Nath, K., NELSON, D. S., Ho, A. M., Lee, S., Darpolor, M. M., Pickup, S., Zhou, R., Heitjan, D. F., Leeper, D. B., & Glickson, J. D. (2012) · NMR in Biomedicine · doi:10.1002/nbm.2824 · Cited by 48
Modification of Recovery from Potentially Lethal X-Ray Damage in Plateau Phase Chinese Hamster Cells
Evans, R. G., Bagshaw, M. A., Gordon, L. F., Kurkjian, S. D., & Hahn, G. M. (1974) · Radiation Research · doi:10.2307/3574076 · Cited by 47
Lonidamine: A Hyperthermic Sensitizer of HeLa Cells in Culture and of the Meth-A Tumor in vivo
Kim, J. H., Kim, S. H., Alfieri, A. A., Young, C. W., & Silvestrini, B. (2009) · Oncology · doi:10.1159/000225882 · Cited by 47
The Specific Role of O 6 -Methylguanine-DNA Methyltransferase Inhibitors in Cancer Chemotherapy
Sun, G., Zhao, L., Zhong, R., & Peng, Y. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0069 · Cited by 47
Self-citation
The differential response of human tumours to fractionated radiation may be due to a post-irradiation repair process
Weichselbaum, R. R., & Little, J. B. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.237 · Cited by 45
Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG)
Kuin, A., Aalders, M. C. G., Lamfers, M. L. M., van Zuidam, D. J., Essers, M., Beijnen, J. H., & Smets, L. A. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690127 · Cited by 45
Reduction of Intracellular pH as a Strategy to Enhance the pH-Dependent Cytotoxic Effects of Melphalan for Human Breast Cancer Cells
Wong, P. W., Lee, C. M., & Tannock, I. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2472 · Cited by 44
A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer
Mansi, J. L., de Graeff, A., Newell, D., Glaholm, J., Button, D., Leach, M. O., Payne, G. S., & Smith, I. E. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.356 · Cited by 44
Matrine Promotes Human Myeloid Leukemia Cells Apoptosis Through Warburg Effect Mediated by Hexokinase 2
Lin, G., Wu, Y., Cai, F., Li, Z., Su, S., Wang, J., Cao, J., & Ma, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01069 · Cited by 42
Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher, B. A., Herman, T. S., Holden, S. A., Epelbaum, R., Liu, S. D., & Frei, E. (1991) · PubMed · Cited by 41
Effect of BCNU pretreatment on diquat-induced oxidant stress and hepatotoxicity
Smith, C. V. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(87)80526-0 · Cited by 41
IL‐1α gene‐transfected human melanoma cells increase tumor‐cell adhesion to endothelial cells and their retention in the lung of nude mice
Chirivi, R. G. S., Chiodoni, C., Musiani, P., Garofalo, A., Bernasconi, S., Colombo, M. P., & Giavazzi, R. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960917)67:6 · Cited by 40
Noninvasive real-time monitoring of intracellular cancer cell metabolism and response to lonidamine treatment using diffusion weighted proton magnetic resonance spectroscopy.
Mardor, Y., Kaplan, O., Sterin, M., Ruı́z-Cabello, J., Ash, E., Roth, Y., Ringel, I., & Cohen, J. S. (2000) · PubMed · Cited by 40
Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment
Jin, X., Zhou, J., Zhang, Z., & Lv, H. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118751 · Cited by 39
FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results
Pacini, P., Rinaldini, M., Algeri, R., Guarneri, A., Tucci, E., Barsanti, G., Neri, B., Bastiani, P., Marzano, S., & Fallai, C. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00068-x · Cited by 38
Inhibition of matrine against gastric cancer cell line MNK45 growth and its anti-tumor mechanism
Luo, C., Zhong, H., Zhu, L., Wu, X. G., Ying, J., Wang, X., LÜ, W. X., Xu, Q., Zhu, Y., & Huang, J. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-1346-5 · Cited by 38
Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria
Chen, H., Chen, F., Hu, W., & Gou, S. (2017) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2017.11.017 · Cited by 37
Male contraceptive Adjudin is a potential anti-cancer drug
Xie, Q. R., Liu, Y., Shao, J., Yang, J., Liu, T., Zhang, T., Wang, B., Mruk, D. D., Silvestrini, B., Cheng, C. Y., et al. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.008 · Cited by 34
A Linear-RBF Multikernel SVM to Classify Big Text Corpora
Romero, R., Iglesias, E. L., & Borrajo, L. (2015) · BioMed Research International · doi:10.1155/2015/878291 · Cited by 33
Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts
Cesare, M. D., Pratesi, G., Giusti, A., Polizzi, D., & Zunino, F. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.69 · Cited by 32
The Rediscovery of DON (6-Diazo-5-oxo-L-norleucine)
Kisner, D. L., Catane, R., & Muggia, F. M. (1980) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-81488-4_30 · Cited by 31
Matrine suppresses cell growth of human chronic myeloid leukemia cells via its inhibition of the interleukin-6/Janus activated kinase/signal transducer and activator of transcription 3 signaling cohort
Ma, L., Zhu, Z., Jiang, L., Sun, X. Y., Lu, X., Zhou, M., Qian, S., & Li, J. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1007507 · Cited by 31
Self-citation
The novel platinum(IV) prodrug with self-assembly property and structure-transformable character against triple-negative breast cancer
Yang, C., Tu, K., Gao, H., Zhang, L., Sun, Y., Yang, T., Kong, L., Ouyang, D., & Zhang, Z. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119751 · Cited by 31
Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids
Cervantes-Madrid, D., & Dueñas‐González, A. (2015) · Oncology Reports · doi:10.3892/or.2015.4077 · Cited by 30
The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia In vitro
Griffiths, M., Keast, D. H., Crawford, M. A., Palmer, T. N., & Patrick, G. J. (1993) · International Journal of Biochemistry · doi:10.1016/0020-711x(88)90303-5 · Cited by 30
Feasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer
Cervantes-Madrid, D., Domínguez-Gómez, G., González‐Fierro, A., Pérez‐Cárdenas, E., Taja‐Chayeb, L., Trejo‐Becerril, C., & Dueñas‐González, A. (2017) · Oncology Letters · doi:10.3892/ol.2017.5615 · Cited by 30
The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes
Davidescu, M., Macchioni, L., Scaramozzino, G., Marchetti, M. C., Migliorati, G., Vitale, R., Corcelli, A., Roberti, R., Castigli, E., & Corazzi, L. (2015) · Scientific Reports · doi:10.1038/srep14343 · Cited by 29
Changes of Energy Metabolism in the Germ Cells and Ehrlich Ascites Tumor Cells
Floridi, A., BELLOCCI, M., Paggi, M. G., Marcante, M. L., & Martino, C. D. (2009) · Chemotherapy · doi:10.1159/000238045 · Cited by 28
The Potential of Combi-Molecules with DNA-Damaging Function as Anticancer Agents
Sun, G., Fan, T., Zhao, L., Zhou, Y., & Zhong, R. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0229 · Cited by 28
Self-citation
Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
Band, P. R., Maroun, J., Pritchard, K. I., Stewart, D. E., Coppin, C., Wilson, K., & Eisenhauer, E. A. (1986) · PubMed · Cited by 27
Effect of lonidamine on the utilization of 14C-labeled glucose by human astrocytoma cells
Paggi, M. G., Zupi, G., Fanciulli, M., Carlo, C. D., Giorno, S., Laudonio, N., Silvestrini, B., Caputo, A., & Floridi, A. (1987) · Experimental and Molecular Pathology · doi:10.1016/0014-4800(87)90070-0 · Cited by 26
Matrine promotes G0/G1 arrest and down-regulates cyclin D1 expression in human rhabdomyosarcoma cells.
Guo, L. M., Xue, T.-Y., Xu, W., & Gao, J.-Z. (2013) · PubMed · Cited by 26
The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy
Guohui, S., Lijiao, Z., & Ru-gang, Z. (2015) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520615666150824160421 · Cited by 25
An enzyme-assisted self-delivery system of lonidamine–peptide conjugates for selectively killing cancer cells
Wu, C., Liu, J., Tang, X., Zhai, Z., Xu, K., & Zhong, W. (2019) · Chemical Communications · doi:10.1039/c9cc06204a · Cited by 23
Phase I Toxicologic Study of Lonidamine in Cancer Patients
Band, P. R., Deschamps, M., Besner, J., Leclaire, R., Gervais, P., & Sanctis, A. D. (2009) · Oncology · doi:10.1159/000225887 · Cited by 22
Glycolytic inhibition by 3-bromopyruvate increases the cytotoxic effects of chloroethylnitrosoureas to human glioma cells and the DNA interstrand cross-links formation
Sun, X., Sun, G., Huang, Y., Zhang, S., Tang, X., Zhang, N., Zhao, L., Zhong, R., & Peng, Y. (2020) · Toxicology · doi:10.1016/j.tox.2020.152413 · Cited by 22
Self-citation
Effects of hyperglycemia on lonidamine‐induced acidification and de‐energization of human melanoma xenografts and sensitization to melphalan
Nath, K., NELSON, D. S., Heitjan, D. F., Zhou, R., Leeper, D. B., & Glickson, J. D. (2015) · NMR in Biomedicine · doi:10.1002/nbm.3260 · Cited by 20
Aplastic Anemia as a Cause of Death in a Patient with Glioblastoma Multiforme Treated with Temozolomide
Kopecký, J., Priester, P., Slováček, L., Petera, J., Kopecký, O., & Macingova, Z. (2010) · Strahlentherapie und Onkologie · doi:10.1007/s00066-010-2132-3 · Cited by 20
Lonidamine: a non-mutagenic antitumor agent
Forster, R. P., Campana, A., D’Onofrio, E., Henderson, L., Mosesso, P., & Barcellona, P. S. (1990) · Carcinogenesis · doi:10.1093/carcin/11.9.1509 · Cited by 20
Micelle System Based on Molecular Economy Principle for Overcoming Multidrug Resistance and Inhibiting Metastasis
Qi, Y., Qin, X., Yang, C., Wu, T., Qiao, Q., Song, Q., & Zhang, Z. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00922 · Cited by 19
Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro.
Ning, S. C., & Hahn, G. M. (1990) · PubMed · Cited by 18
How Mainstream Medicine Sees Photodynamic Therapy in the United Kingdom
Bown, S. G. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0180 · Cited by 18
A prospective randomized comparison of radiation therapy plus lonidamine versus radiation therapy plus placebo as initial treatment of clinically localized but nonresectable nonsmall cell lung cancer
Scarantino, C. W., McCunniff, A. J., Evans, G., Young, C. W., & Paggiarino, D. A. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90394-8 · Cited by 17
In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines
Savini, S., Zoli, W., Nanni, O., Volpi, A., Frassineti, G. L., Magni, E., Flamigni, A., Amadori, A., & Amadori, D. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01832355 · Cited by 17
Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo.
Ning, S. C., & Hahn, G. M. (1991) · PubMed · Cited by 15
Potentiation of radiation effects on multicellular tumor spheroids (mts) of hela cells by lonidamine
Kim, J. H., Kim, S. H., He, S.-Q., Alfieri, A. A., & Young, C. W. (1989) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(89)90298-8 · Cited by 14
Weekly epirubicin plus lonidamine in advanced breast carcinoma
Nisticò, C., Garufi, C., Milella, M., D'Ottavio, A. M., Vaccaro, A., Fabi, A., & Terzoli, E. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006213815195 · Cited by 14
Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide
Nath, K., NELSON, D. S., Roman, J., Putt, M. E., Lee, S., Leeper, D. B., & Glickson, J. D. (2017) · Anticancer Research · doi:10.21873/anticanres.11708 · Cited by 14
Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin
Nath, K., Roman, J., NELSON, D. S., Guo, L., Lee, S., Orlovskiy, S., Muriuki, K., Heitjan, D. F., Pickup, S., Leeper, D. B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33019-4 · Cited by 13
Enhancement of sensitivity to hyperthermia by Lonidamine in human cancer cells
Raaphorst, G. P., Feeley, M., Martin, L., Danjoux, C. E., Maroun, J., Desanctis, A. J., & Ko, D. (1991) · International Journal of Hyperthermia · doi:10.3109/02656739109056445 · Cited by 12
Thermal sensitisation by lonidamine of human melanoma cells grown at low extracellular pH
Coss, R. A., Storck, C., Wells, T. C., Kulp, K. A., Wahl, M., & Leeper, D. B. (2013) · International Journal of Hyperthermia · doi:10.3109/02656736.2013.858832 · Cited by 11
The Blepharis persica seed hydroalcoholic extract synergistically enhances the apoptotic effect of doxorubicin in human colon cancer and gastric cancer cells
Aghaabbasi, K., Askari, N., Kumleh, H. H., Torkzadeh‐Mahani, M., & Ghara, A. R. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04711-z · Cited by 11
Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice
Nath, K., NELSON, D. S., Putt, M., Leeper, D. B., Garman, B., Nathanson, K. L., & Glickson, J. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157125 · Cited by 10
Enhancement of hyperthermic toxicity by lonidarnine in the dunning R3327G rat prostatic adenocarcinoma
Bloch, W. E., Lokeshwar, B. L., FERRELL, S. M., & Block, N. L. (1994) · The Prostate · doi:10.1002/pros.2990240306 · Cited by 9
Effect of daunorubicin on acute promyelocytic leukemia cells using nuclear magnetic resonance spectroscopy-based metabolomics
Nong, Q., Zhang, C., Liu, Q., Xie, R., & Dong, M. (2020) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2020.103382 · Cited by 6

Research works printed but not linked: 4

Cioli, 1980, Anti-spermogenic activity of lonidamine (AF-1890) in rabbit, Ultramicroscopy, 5, 418
Lin, 2011, The progress of the platinum antitumor drugs and clinical evaluation, Eval. Anal. Drug Use Hosp. China, 11, 4
Yu, 2010, LND and NP regimen treament for advanced non-small cell lung cancer, Chin. Clin. Oncol., 37, 763
Zhang, 2016, Research progress on the relationship between tumor microenvironment and radiosensitivity of tumor cells, J. Jilin. Univ. Med. Edit., 42, 1038

Sorted by citations

Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?
Singh, M., Afonso, J., Sharma, D., Gupta, R., Kumar, V., Rani, R., Baltazar, F., & Kumar, V. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.007 · Cited by 194
Dysregulation of metabolic pathways in pulmonary fibrosis
Rajesh, R., Atallah, R., & Bärnthaler, T. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108436 · Cited by 132
The Warburg effect: a score for many instruments in the concert of cancer and cancer niche cells
Jaworska, M., Szczudło, J., Pietrzyk, A., Shah, J., Trojan, S., Ostrowska, B., & Kocemba‐Pilarczyk, K. A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00504-1 · Cited by 128
Mitochondria-Targeted Multifunctional Nanoprodrugs by Inhibiting Metabolic Reprogramming for Combating Cisplatin-Resistant Lung Cancer
Lu, H., Tong, W., Jiang, M., Liu, H., Meng, C., Wang, K., & Mu, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c04024 · Cited by 92
Nanomaterial-enabled metabolic reprogramming strategies for boosting antitumor immunity
Ma, M., Zhang, Y., Pu, K., & Tang, W. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00679h · Cited by 100

See all 124

Authors: Huang, Y., Sun, G., Sun, X., Li, F., Zhao, L., Zhong, R., & Peng, Y.
Affiliations: Beijing University of Technology (CN)
Corresponding author: Sun, Guohui
ORCID: Sun, Guohui
Li, Feifan
Zhao, Lijiao
Venue: Cancers
Publisher: MDPI AG
Published: 2020-11-11
Volume: 12
Issue: 11
Pages: 3332
ISSN: 2072-6694 (ISSN-L)
DOI: 10.3390/cancers12113332
PMC: PMC7696079
OpenAlex: W3105923034
Cited by: 124
References: 119
Citations by year: 2026: 15 · 2025: 32 · 2024: 25 · 2023: 27 · 2022: 15 · 2021: 10
FWCI: 1.33
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Cancers (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Natural Science Foundation of China (82003599, 21778011)
Science and Technology General Project of Beijing Municipal Education Commission (KM202110005005)
Beijing Natural Science Foundation (7184192)
Beijing Postdoctoral Research Foundation (2018-ZZ-022, ZZ2019-30)
the Great Wall Scholars Program of Beijing Municipal Education Commission (CIT&TCD20180308)
Science and Technology Key Project of Beijing Municipal Education Commission (PXM2015_014204_500175)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Keywords: lonidamine, adjudin, chemosensitization, cancer energy metabolism, mitochondrial pyruvate carrier, mitochondrial permeability transition pore, hexokinase 2, chemoresistance, radiosensitization, hyperthermia, photodynamic therapy, combination therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks